文献速递产科

2019至2021年美国围产期氨甲环酸使用趋势更新

An update to tranexamic acid trends during the peripartum period in the United States, 2019 to 2021.
PubMed 文献 · Am J Obstet Gynecol MFM · 2023-03-16

该回顾性队列研究纳入美国19家医院50150例分娩患者,2019年7月至2021年6月期间3.2%(1580/50150)接受氨甲环酸。西部区域使用增加,接受者更常有产后出血史、慢性高血压、子痫前期和糖尿病。接受氨甲环酸者静脉血栓栓塞发生率与未接受者无显著差异(8[0.5%] vs 226[0.5%];P=.77)。

要点

  • 分娩患者中3.2%(1580/50150)接受了氨甲环酸。
  • 西部区域两年研究期间氨甲环酸使用增加。
  • 接受氨甲环酸者静脉血栓栓塞风险未增加(P=.77)。

核心结论

  • 全国范围内,与既往研究相比,更高比例的患者在没有产后出血诊断的情况下接受了氨甲环酸,且美国西部区域分娩期间氨甲环酸使用总体较前几年增加。
  • 无论有无产后出血诊断,接受氨甲环酸者静脉血栓栓塞风险均未增加。

研究设计与样本

  • 回顾性队列研究,纳入Universal Health Services, Incorporated网络内19家医院,划分为东部、中部和西部地理区域。
  • 比较2019年7月至2021年6月期间的氨甲环酸使用率,并分析接受者的患者人口学特征和围产期结局。

主要发现

  • 两年研究期间,3.2%(1580/50150)的分娩患者接受了氨甲环酸。
  • 美国西部区域在两年研究期间氨甲环酸使用增加。
  • 接受氨甲环酸者更常有产后出血史(P<.0001)、慢性高血压(P<.0001)、子痫前期(P<.0001)和/或糖尿病(P=.004)。
  • 接受氨甲环酸者与未接受者相比,静脉血栓栓塞发生率无显著差异(8[0.5%] vs 226[0.5%];P=.77)。
  • 接受氨甲环酸者中,53.2%(840/1580)的估计失血量<1000 mL。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Results from the 2017 World Maternal Antifibrinolytic trial found that patients who received tranexamic acid during delivery had significantly lower rates of death and hysterectomy. Several months after the World Maternal Antifibrinolytic trial publication, American College of Obstetricians and Gynecologists endorsed the consideration of tranexamic acid usage when traditional uterotonics fail during postpartum hemorrhage. Since then, tranexamic acid usage has become more mainstream for the treatment of postpartum hemorrhage. OBJECTIVE: This study aimed to evaluate tranexamic acid trends in obstetrics both temporally and geographically within the United States. Additional outcomes included patient demographics and perinatal outcomes. STUDY DESIGN: This retrospective cohort study included 19 hospitals divided into East, Central, and West geographic regions within the Universal Health Services, Incorporated network. Rates of tranexamic acid use were compared from July 2019 through June 2021. Patient demographics and perinatal outcomes were analyzed for tranexamic acid recipients. RESULTS: During the two-year study period, 3.2% (1580/50,150) of patients received tranexamic acid during delivery. The western region of the United States demonstrated increased tranexamic acid use over the 2-year study period. Recipients of tranexamic acid were more likely to have a history of postpartum hemorrhage (P<.0001), chronic hypertension (P<.0001), preeclampsia (P<.0001), and/or diabetes (P=.004). Patients who received tranexamic acid did not have an increased likelihood of venous thromboembolism in comparison with those who did not receive tranexamic acid (8 [0.5%] vs 226 [0.5%]; P=.77). Of those who received tranexamic acid, 53.2% (840/1580) had an estimated blood loss <1000 mL. CONCLUSION: Nationally, a higher percentage of patients received tranexamic acid without a postpartum hemorrhage diagnosis compared with previous studies, and the western region of the United States had an overall increased use of tranexamic acid during delivery compared with previous years. There was no increased risk of venous thromboembolism in those who received tranexamic acid, regardless of postpartum hemorrhage diagnosis.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Sterling EK, Litman EA, Dazelle WDH, et al. An update to tranexamic acid trends during the peripartum period in the United States, 2019 to 2021. Am J Obstet Gynecol MFM. 2023. PMID: 36933804. doi:10.1016/j.ajogmf.2023.100933

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。